Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) have announced positive outcomes from the Phase III WAYPOINT trial of TEZSPIRE (tezepelumab) for patients with severe chronic ...

Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

On his YouTube channel, "Destino Tolk," the Dominican influencer shared with his colleague Fernan the details of the incident, clarifying that what was initially supposed to be a polyp removal turned ...

The effort to prevent the certification of Electoral College votes on January 6, 2021, was legally possible because of loopholes in the Electoral Count Act of 1887 that some Republicans exploited ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, ...

Abstract: Early diagnosis of colorectal polyps, before they turn into cancer, is one of the main keys to treatment. In this work, we propose a framework to help radiologists in reading CT scans and ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...